Literature DB >> 10372695

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

P J Snyder1, H Peachey, P Hannoush, J A Berlin, L Loh, J H Holmes, A Dlewati, J Staley, J Santanna, S C Kapoor, M F Attie, J G Haddad, B L Strom.   

Abstract

As men age, their serum testosterone concentrations decrease, as do their bone densities. Because bone density is also low in hypogonadal men, we hypothesized that increasing the serum testosterone concentrations of men over 65 yr to those found in young men would increase their bone densities. We randomized 108 men over 65 yr of age to wear either a testosterone patch or a placebo patch double blindly for 36 months. We measured bone mineral density by dual energy x-ray absorptiometry before and during treatment. Ninety-six men completed the entire 36-month protocol. The mean serum testosterone concentration in the men treated with testosterone increased from 367 +/- 79 ng/dL (+/-SD; 12.7 +/- 2.7 nmol/L) before treatment to 625 +/- 249 ng/dL (21.7 +/- 8.6 nmol/L; P < 0.001) at 6 months of treatment and remained at that level for the duration of the study. The mean bone mineral density of the lumbar spine increased (P < 0.001) in both the placebo-treated (2.5 +/- 0.6%) and testosterone-treated (4.2 +/- 0.8%) groups, but the mean changes did not differ between the groups. Linear regression analysis, however, demonstrated that the lower the pretreatment serum testosterone concentration, the greater the effect of testosterone treatment on lumbar spine bone density from 0-36 months (P = 0.02). This analysis showed a minimal effect (0.9 +/- 1.0%) of testosterone treatment on bone mineral density for a pretreatment serum testosterone concentration of 400 ng/dL (13.9 nmol/L), but an increase of 5.9 +/- 2.2% for a pretreatment testosterone concentration of 200 ng/dL (6.9 nmol/L). Increasing the serum testosterone concentrations of normal men over 65 yr of age to the midnormal range for young men did not increase lumbar spine bone density overall, but did increase it in those men with low pretreatment serum testosterone concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372695     DOI: 10.1210/jcem.84.6.5741

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  127 in total

1.  For and against: The male menopause--does it exist?

Authors:  D C Gould; R Petty; H S Jacobs
Journal:  BMJ       Date:  2000-03-25

2.  The male menopause: does it exist?: against: problems of senescence in men are not analogous to female menopause

Authors: 
Journal:  West J Med       Date:  2000-08

Review 3.  Osteoporosis in men.

Authors:  G M Prelevic
Journal:  J R Soc Med       Date:  2001-12       Impact factor: 5.344

Review 4.  Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review.

Authors:  Tom E Nightingale; Pamela Moore; Joshua Harman; Refka Khalil; Ranjodh S Gill; Teodoro Castillo; Robert A Adler; Ashraf S Gorgey
Journal:  J Spinal Cord Med       Date:  2017-08-03       Impact factor: 1.985

Review 5.  Osteoporosis in men: are we ready to diagnose and treat?

Authors:  H M Perry; J E Morley
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 6.  Andropause: to treat or not to treat?

Authors:  S Basaria; A Dobs
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 7.  Effects of androgen replacement on metabolism and physical performances in male hypogonadism.

Authors:  M Zitzmann; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 8.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

9.  Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.

Authors:  Anne M Kenny; Alison Kleppinger; Kristen Annis; Margaret Rathier; Bruce Browner; James O Judge; Daniel McGee
Journal:  J Am Geriatr Soc       Date:  2010-06       Impact factor: 5.562

Review 10.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.